NCT01428115View on ClinicalTrials.gov

Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab

CompletedOBSERVATIONAL
Enrollment

83

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Severe Crohn's DiseaseAnxiety
Trial Locations (8)

1030

Site Reference ID/Investigator# 47342, Vienna

1090

Site Reference ID/Investigator# 64833, Vienna

3100

Site Reference ID/Investigator# 64828, Sankt Pölten

6020

Site Reference ID/Investigator# 64832, Innsbruck

8036

Site Reference ID/Investigator# 64830, Graz

9300

Site Reference ID/Investigator# 79613, Saint Veit/Glan

A-4010

Site Reference ID/Investigator# 64829, Linz

A-5020

Site Reference ID/Investigator# 64831, Salzburg

All Listed Sponsors
collaborator

Raffeiner GmbH

INDUSTRY

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01428115 - Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab | Biotech Hunter | Biotech Hunter